Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: ACLS THER

Market Cap 603M 521M 480M 449M 842M 57.35B 855M 5.67B 2.21B 27.91B 2.26B 2.22B 96.65B P/E Ratio 2026 *
-6.66x
P/E Ratio 2027 * -5.42x
Enterprise Value 468M 404M 372M 348M 653M 44.46B 663M 4.4B 1.71B 21.64B 1.76B 1.72B 74.93B EV / Sales 2026 *
81.9x
EV / Sales 2027 * 89.3x
Free-Float
97.72%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 16/01/2024
President 67 17/11/2024
Director of Finance/CFO 39 31/12/2022
Director TitleAgeSince
Chairman 56 31/12/2022
Chairman 60 31/05/2019
Director/Board Member 50 31/08/2014
Change 5-day change 1-year change 3-year change Capi.($)
+1.03%+2.30%+55.91%+114.22% 56.42B
+2.72%+3.26%+46.05%+44.91% 44.54B
+1.12%+2.79%-15.04%-21.68% 22.9B
+1.17%+3.85%-0.89%+403.86% 21.21B
+3.81%-5.07%+11.00%-30.62% 16.4B
+0.15%+2.24%+9.32%-39.30% 15.4B
-0.69%+0.82%+27.75%+176.72% 13.35B
+5.27%+5.54%+19.65% - 12.36B
+1.61%+1.28%+95.75%+205.26% 11.15B
Average +1.80%+2.09%+27.72%+106.67% 23.75B
Weighted average by Cap. +1.72%+2.37%+32.04%+99.60%

Financials

2026 *2027 *
Net sales 5.71M 4.93M 4.55M 4.26M 7.98M 543M 8.1M 53.69M 20.93M 264M 21.44M 20.98M 915M 5.36M 4.63M 4.26M 3.99M 7.48M 509M 7.6M 50.36M 19.63M 248M 20.11M 19.68M 858M
Net income -84.78M -73.23M -67.48M -63.16M -118M -8.06B -120M -797M -311M -3.92B -318M -311M -13.58B -103M -88.54M -81.59M -76.37M -143M -9.74B -145M -963M -376M -4.74B -385M -377M -16.42B
Net Debt -136M -117M -108M -101M -189M -12.89B -192M -1.27B -497M -6.27B -509M -498M -21.72B -125M -108M -99.41M -93.05M -174M -11.87B -177M -1.17B -458M -5.78B -469M -459M -20.01B
Logo ACLS THER
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!